Abstract Acetylcholinesterase (AChE) is a key enzyme in the cholinergic nervous system and is one of the most studied proteins in the field of Alzheimer's disease (AD). Moreover, alternative functions of AChE unrelated with the hydrolysis of acetylcholine are suspected. Until now, the majority of investigations on AChE in AD pathology have been focused on the determination of its enzymatic activity level, which is depleted in the AD brain. Despite this overall decrease, AChE activity increases at the vicinity of the two hallmarks of AD, the amyloid plaques and the neurofibrillary tangles (NFT). In fact, AChE may directly interact with Aβ in a manner that increases the deposition of Aβ to form plaques. In the context of protein-protein interactions, we have recently reported that AChE can interact with presenilin-1, the catalytic component of γ-secretase, influencing its expression level and also its activity. However, the alteration of AChE protein in the AD brain has not been determined. Here, we demonstrated by Western blotting and immunohistochemistry that a prominent pool of enzymatically inactive AChE protein existed in the AD brain. The potential significance of these unexpected levels of inactive AChE protein in the AD brain was discussed, especially in the context of protein-protein interactions with β-amyloid and presenilin-1.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition. Cholinergic depletion is a classical feature in the AD brain, associated with amyloid plaques and neurofibrillary tangles (NFT) (Davies and Maloney 1976; Perry et al. 1977) . A decrease in acetylcholinesterase (AChE), the enzyme that rapidly degrades the neurotransmitter acetylcholine at cholinergic synapses, has been reported in a large number of studies (for a review, see García-Ayllón et al. 2011) . Nonetheless, because of the substantial reduction in acetylcholine levels, a molecule with a critical role in cognitive function, the therapies designed to reverse the cholinergic deficit characteristics of AD are based on inhibitors of AChE (AChE-I) (Giacobini 2003; Lleó et al. 2006) . Furthermore, evidence indicates that cholinergic mechanisms can modulate amyloid metabolism (Nitsch et al. 1992; Rossner et al. 1998 ) and AChE-I affect the amyloid expression (Mori et al. 1995; Zimmermann et al. 2005; Lahiri et al. 1997) , although the therapeutic effect of present AChE-I drugs used in AD therapy is rather modest and has not met expectations (Small 2005) .
The majority of investigations about AChE on AD progression and therapy have been based on the determination of its enzymatic activity level. However, AChE is much more than a cholinergic enzyme, and indeed other biological functions unrelated with its catalytic activity have been reported (Sternfeld et al. 1998; Dori et al. 2005; Grisaru et al. 2006) . These alternative functions are probably related with the rich polymorphism of AChE that exists in different variants by alternative splicing, as well as the existence of different molecular forms (for a review, see Massoulié 2002) . Moreover, AChE is present in noncholinergic tissues and shares with several neural cell adhesion proteins high sequence similarity (Krejci et al. 1991) . The presence of a cholinesterase-like domain in those adhesion proteins may reflect the capacity of AChE in acting in protein-protein interactions.
We have recently demonstrated an interaction between AChE and presenilin-1 (PS1), the catalytic component of the γ-secretase complex (Silveyra et al. 2008 (Silveyra et al. , 2012a . γ-Secretase is a proteolytic enzymatic complex that participates in the processing of the amyloid precursor protein (APP), generating the β-amyloid peptide or Aβ (Kaether et al. 2006) , the major constituent of the amyloid plaques (Masters et al. 1985; Kang et al. 1987) . Moreover, extensive studies by Inestrosa and co-workers showed that AChE directly interacted with Aβ (Alvarez et al. 1995; Inestrosa et al. 1996a, b) . Indeed, despite the overall decrease in the AD brain, AChE is increased at the vicinity of amyloid plaques and NFT (Ulrich et al. 1990; Gomez-Ramos et al. 1992; Wright et al. 1993) . The pathological implications of these and other AChE-amyloid interrelationships have remained elusive, but it is evident that AChE can influence amyloid processing and fibrillation via protein-protein interactions and not only through its cholinergic activity. Accordingly, new dual binding AChE-I, able to inhibit the AChE-induced Aβ aggregation, are in development (García-Palomero et al. 2008; Belluti et al. 2011; Viayna et al. 2013) . In this context, it has been recently demonstrated that a novel AChE-I, NP-9 (9-anthraldehyde pyrazoline derivative), which is able to interfere Aβ AChE interaction, attenuates Aβ aggregation and amyloid-induced toxicity in Alzheimer animal models (Mishra et al. 2013) .
Surprisingly, the vast majority of AChE studies in the AD brain, including histological studies, are focused on the AChE enzymatic level and not the protein level. Here, we present evidence that, in the AD brain, the level of AChE protein does not accord with the decrease in enzymatic activity level. We also discuss the potential physiopathological consequences of the presence of this unexpected large pool of nonenzymatically active AChE in the pathological brain. Braak and Braak (1991) . Samples from nondisease individuals correspond to cases with no clinical dementia and no evidence of brain pathology. The mean postmortem interval of the tissue was between 1.5 and 6 h, with no significant difference between each group of samples.
Material and Methods

Collection
Preparation of Human Brain Samples for Biochemical Analysis
Samples (~0.1 g) of human frontal cortex, stored at −80°C, were thawed slowly at 4°C and homogenized (10 %v/v) in 50 mM Tris-HCl, pH 7.5/150 mM NaCl/5 mM EDTA/1 % (w /v ) Nonidet P-40/0.5 % (w/v) Triton X-100 and supplemented with a cocktail of protease inhibitors (Sáez-Valero et al. 1993) . The homogenates were sonicated and centrifuged at 70,000×g at 4°C for 1 h, and the supernatants were collected and frozen at −80°C until assay.
AChE Enzymatic Assay and Protein Determination
A modified microassay version of the colorimetric Ellman's method was used to measure AChE (Sáez-Valero et al. 1993 ), using 50 μM tetraisopropyl pyrophosphoramide (iso-OMPA) as specific inhibitor for the structurally related butyrylcholinesterase, an enzyme that coexists with AChE in the human brain. One milliunit (mU) of AChE activity was defined as the number of nanomoles of acetylthiocholine hydrolyzed per minute at 22°C. Total protein concentrations were determined using the bicinchoninic acid method (Pierce). AChE-specific activity is expressed as the activity of the enzyme in milliunits per milligram (mg) of total protein (mU/mg).
Western Blotting Assays
Fifty micrograms of protein from brain extracts (equal amount of protein in each lane) was separated by SDS-PAGE electrophoresis. Samples were denatured at 98°C for 7 min. The separated proteins were transferred to nitrocellulose membranes (Schleicher & Schuell Bioscience GmbH) and probed with the goat anti-AChE antibody N19 (Santa Cruz Biotech) and rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Abcam). The blots were incubated with the corresponding secondary antibody conjugated to horseradish peroxidase, and the signal was detected using ECL Plus detection reagent according to the manufacturer's instructions (GE Healthcare) in a Luminescent Image Analyzer LAS-1000 Plus (FUJIFILM). For semiquantitative analysis, protein levels were normalized to GAPDH, and the intensity of the bands was measured by densitometry with the Science Lab Image Gauge v4.0 software provided by FUJIFILM.
Preparation of Human Brain Samples for Immunohistochemistry and Histochemistry
Upon removal, the brain tissue was immediately fixed in cold 4 % paraformaldehyde in phosphate buffer (PB 0.1 M, pH 7.4), and after 2 h, the tissue was cut into small blocks and post-fixed in the same fixative for 24-48 h at 4°C. After fixation, all the specimens were immersed in graded sucrose solutions, and they were stored in a cryoprotectant solution at −20°C. Serial vibratome sections (50 μm) of cortical tissue were obtained, and the sections from each region and case were batch-processed for immunocytochemical staining. The sections immediately adjacent to those stained immunocytochemically were Nissl-stained so as to identify the cortical areas to which they pertained and the laminar boundaries. The same AD and ND cases were extensively studied by scores for the amyloid and neurofibrillary pathologies, as in a previous study (Blazquez-Llorca et al. 2011 ).
Immunohistochemistry and Staining Procedure
Free-floating hippocampal sections were pretreated in 1 % H 2 O 2 for 30 min to remove endogenous peroxidase activity, and subsequently, they were blocked for 1 h in PB with 0.25 % Triton-X and 3 % normal rabbit serum (1:200, Vector Laboratories Inc.). The sections were incubated overnight at 4°C with the N19 (1:500) antibody, and the following day, the sections were rinsed and incubated for 2 h with biotinylated rabbit anti-goat IgG (1:200, BA-5000, Vector Laboratories). The sections were then incubated for 1 h in an avidin-biotin peroxidase complex (Vectastain ABC Elite PK6100, Vector) and finally with the 3,3′-diaminobenzidine tetrahydrochloride chromogen (DAB, Sigma-Aldrich). After staining, the sections were dehydrated, cleared with xylene, and coverslipped. Control sections were processed as above but without the primary antibodies, and no significant staining was seen under these conditions. The AChE enzymatic reaction was performed according to the method of Karnovsky and Roots (1964) . Slices were incubated for 2 h in the medium containing the following: acetylthiocholine iodide (0.05 %), 5 mM K 3 Fe(CN) 4 (0.164 %), 30 mM CuSO 4 (0.75 %), and 0.1 mM sodium citrate (2.94 %) in 0.2 M acetate buffer (pH 6.0) (1.64 %). The reaction was stopped with washes in phosphate-buffered saline. Then, the sections were dehydrated, cleared with xylene, and coverslipped.
Statistical Analysis
All data were analyzed using SigmaStat (Version 2.0; SPSS Inc.) by Student's t test (two tailed). Results are presented as means ± SEM. p values<0.05 were considered significant.
Results
The levels of AChE in frontal cortex extracts from AD and ND subjects were screened for enzymatic activity. As expected, the AChE assay revealed that AD samples had lower enzymatic activity (40 % decrease; p =0.003), in comparison to age-and gender-matched ND controls (Fig. 1a) .
Sample aliquots were analyzed by SDS-PAGE under fully reducing conditions, followed by Western blotting using antiAChE antibody N19, raised against a peptide that maps the Nterminus of human AChE, common to all variants. N19 detected AChE bands of~75 and~65 kDa and a doublet of bands at~55 and~50 kDa in brain samples from both AD and nondisease (ND) control subjects (Fig. 1b) . Although the predicted molecular weight of the AChE subunits is 70 kDa in size, our as well as other studies strongly suggest the identity of lower AChE molecular weight bands (García-Ayllón et al. 2006 Santos et al. 2007; Sternfeld et al. 2000; Xie et al. 2011) . The lower molecular weight bands might originate by posttranslation modification and/or resulted from the reducing conditions used during electrophoresis. We have previously confirmed the specificity of the AChE bands, including the lighter subunits, by AChE immunoprecipitation and probing blots with alternative antihuman AChE antibodies (García-Ayllón et al. 2007 . Interestingly, the decrease in AChE enzyme activity was not paralleled by changes in AChE protein immunoreactivity. The levels of immunoreactive AChE bands were not significantly different in AD samples in comparison with ND controls (Fig. 1b) . Immunohistochemical examination of AD brain yielded similar results (Fig. 2) .
The AChE protein staining pattern was studied in hippocampus from three AD patients and one ND control case. Sections from AD and control brain showed similar immunoreactivity to the anti-AChE antibody N19. Moreover, AChE-positive fibers stained with the N19 antibody seemed to be denser around amyloid plaques in AD patients (Fig. 2b) , when compared with other regions far from the plaque or the control case. Similar to previous reports (Ulrich et al. 1990; Gomez-Ramos et al. 1992; Wright et al. 1993) , when the AChE enzymatic reaction was performed by the Karnovsky and Roots method (Karnovsky and Roots 1964) , no fibers were observed, but the amyloid plaques and NFT were stained (Fig. 2b, inset) .
Discussion
Here we report that AChE protein level appears unexpectedly preserved in the AD brain, with respect to the decline in activity level. Frontal cortex samples, assayed by immunoblotting, and hippocampus sections, resolved by immunohistochemistry, demonstrate that AChE protein levels are comparable between AD and ND subjects. Despite the limitation of the low number of samples analyzed, our data signify discrepancies between the levels of AChE activity and AChE protein immunoreactivity, which may be attributable in part to the inactive or subnormal active character of AChE subunits present in the pathological tissues. Moreover, AChE banding pattern obtained by electrophoretic analysis/Western blotting has no simple relationship to specific molecular forms or enzymatic activity (García-Ayllón et al. 2006 . For this reason, the detriment in the major tetrameric form of AChE is not patent in immunoreactivity changes of particular bands. Further analyses with antibodies for specific variants are pending.
There is an extensive number of investigations being done to identify alterations in AChE level as a consequence of AD processes. Most of them are based on biochemical determination of enzymatic activity, probably because of the facility in measuring the activity of the enzyme and also because of the interest derived from the use of AChE-I in therapy. Today, it is well established that a substantial loss of AChE activity is due to loss of a tetrameric form linked to the plasma membrane (Atack et al. 1983; Sáez-Valero et al. 1999) . Enzymatic histochemical Fig. 1 Decrease in AChE activity does not parallel changes in AChE protein in the Alzheimer's brain. a AChE activity levels in frontal cortex extracts from nondemented (ND) controls (n =5) and patients with Alzheimer's disease (AD) (n =5). b Aliquots of the same brain extracts were immunoblotted with the anti-AChE antibody N19, which recognizes all variants. Representative immunoblot (left panel) and densitometric quantification (right panel) of the AChE-immunoreactive bands, expressed in arbitrary units (a.u.) , are shown and expressed as percentage relative to immunoreactivity of the 75-kDa band from the ND group. For the semiquantitative analysis, protein levels were normalized to GAPDH. The results were confirmed in two independent determinations with equivalent amounts of protein loaded in each lane. Columns represent means ± SEM. *p <0.05, significantly different from the ND group Fig. 2 Immunohistochemical detection of AChE in human hippocampus. Immunostaining with the anti-AChE antibody N19, in the subiculum from a control case (a) and an AD patient (b). Inset in b corresponds to AChE enzymatic reaction in the subiculum from the same AD subject. AChE-positive fibers stained with the N19 antibody seem to be denser around amyloid plaques (surrounded by arrowheads). When the AChE enzymatic reaction was performed, no fibers were observed, but the amyloid plaques and NFT (inset in b) were stained. Scale bar =35 μm in a, b; 80 μm in inset in b examination of the AD brain yielded similar results than biochemical determination with an overall depletion of AChE activity (Ulrich et al. 1990; Gomez-Ramos et al. 1992; Wright et al. 1993) . In vivo studies by positron emission tomography, based on the assessment of enzymatic activity using radiolabeled analogs of acetylcholine, also suggested that AChE activity could be reduced in the AD brain (Iyo et al. 1997; Herholz 2008; Mori et al. 2012) .
Several laboratories attempted to develop an enzymelinked immunosorbent assay (ELISA) for AChE (Rasmussen et al. 1989; Blennow et al. 2007; Darreh-Shori et al. 2008) , but very few develop a two-site immunoassay (Brimijoin et al. 1987; Weikert et al. 1994; Konings et al. 1995) . Hammond and Brimijoin (1988) reported a parallel variation in AChE enzyme activity and AChE immunoreactivity, assessed by a two-site ELISA in the AD brain, but this ELISA probably assessed only protein levels for the major tetrameric form. Previously, we had noted that a large amount of AChE subunits found in AD samples and identified by Western blotting with several polyclonal anti-AChE antibodies, displayed low affinity for certain monoclonal antibodies, which recognized native AChE (Sáez-Valero et al. 2000; García-Ayllón et al. 2007 . As commented above, the lack of correlation between catalytic activity and immunostaining may be attributable, at least in part, to the presence of a large amount of inactive AChE subunits.
The existence of inactive AChE has been demonstrated in the brain (Chatel et al. 1993 ). These inactive AChE species are probably monomers, which could serve as a reservoir for the active enzyme (Stieger et al. 1987; Rotundo 1988) . Anyhow, the presence of a large amount of inactive monomers in fluids, such as cerebrospinal fluid (CSF) and plasma (Darreh-Shori et al. 2004; García-Ayllón et al. 2007 , suggests that these light species might have more than a simple role as precursors of enzymatically active oligomers. Despite several evidences strongly supporting the possibility that AChE can act independently of acetylcholine hydrolysis, the physiological significance of the nonenzymatic AChE in the brain is still controversial, as catalytic and noncatalytic effects cannot be easily distinguished (reviewed in Massoulié et al. 1993; Balasubramanian and Bhanumathy 1993; Small et al. 1996; Layer 1995; Soreq and Seidman 2001; Greenfield et al. 2008) . Indeed, transgenic overexpression of enzymatically inactivated AChE (Sternfeld et al. 1998; Dori et al. 2005; Grisaru et al. 2006) or heat-inactivated AChE (Klegeris et al. 1994 ) has demonstrated to exert distinct biological functions. Possible biological functions for the pool of AChE nonenzymatically active in the normal brain, and particularly in the AD brain, therefore need to be elucidated.
The occurrence of AChE subnormal active in the pathological tissue cannot be discarded. In this context, AChE activity present in the AD brain associated with plaques and NFT displays particular enzymatic properties and sensitivity to inhibitors (Geula and Mesulam 1989; Wright et al. 1993) . However, it is not clear whether the atypical histochemical behavior of AChE observed in AD is due to alterations in kinetic properties of these enzymes (Ciro et al. 2012) , or due to interactions with other molecules within these lesions (Darvesh et al. 2010) . In the context of the presence of AChE within plaques and NFT, it is important to note that both AD effectors, Aβ and abnormally hyperphosphorylated tau, can influence AChE levels in vitro Sáez-Valero et al. 2003; Hu et al. 2003; Melo et al. 2003) and in rodent models (Sberna et al. 1998; Sáez-Valero et al. 2002; Silveyra et al. 2012b; Kreutz et al. 2013) . We have also demonstrated that Aβ alters AChE glycosylation in vivo (Sberna et al. 1998; Fodero et al. 2002) , and this change is similar to the change in the glycosylation pattern of AChE in AD brain , 1999 . Correct glycosylation determines the adequate biological function by influencing trafficking, folding, assembly, and final localization of glycoproteins. Changes in glycosylation could compromise enzymatic capacities. The glycosylation pattern of the inactive AChE pool in Alzheimer's condition has not been studied.
Noncatalytic AChE is not the unique AChE pool that remains unaltered, or even increase, in the AD brain. The significance of different variants and forms of AChE is intriguing, as their specific subcellular distribution is thought to reflect specific physiological functions. Despite the loss of the major tetrameric and cholinergic AChE, the minor monomeric form increases in respect to the normal levels in nonpathological brain (Atack et al. 1983; Arendt et al. 1992; Sáez-Valero et al. 1999) . So far, the significance of an increase in minor AChE species is controversial, as the relative increase is compared in absolute terms with the major cholinergic form. However, a variation in a particular AChE form (with little impact on cholinergic equilibrium) could have an impact at the functional level with biological consequences, since particular forms or variants may have specific functions. Indeed, recent evidences indicate distinct and, in certain cases, inverse cell fate outcome under enforced expression of the human N-and C-terminally modified AChE variants, all of which have similar enzymatic activities Toiber et al. 2008; Greenberg et al. 2010) . Brain AChE splice variants show indistinguishable enzymatic activity, but may present particular banding pattern by Western blotting (Meshorer and Soreq 2006) . Additional studies regarding the specific roles of particular AChE species are mandatory in order to develop more effective therapies. In this regard, targeting a specific AChE variant (e.g., by antisense or siRNA agents) could hence offer specific advantages. Indeed, the AChE-targeted microRNA-132 has been recently reported to be downregulated during the progression of AD (Lau et al. 2013) , and the possibility to intercept microRNA-132-mediated damages by modulating AChE expression has been demonstrated viable (Shaltiel et al. 2013 ).
The interaction of AChE with the catalytic subunit of the γ-secretase complex, PS1, is also of interest. We have demonstrated the reciprocal co-immunoprecipitation of AChE with PS1 (Silveyra et al. 2008 ) and the modulation of PS1 levels by AChE-I (Silveyra et al. 2012a ). More interestingly, we have recently seen changes in PS1 levels under the influence of AChE genetic expression (Silveyra et al. 2012a) , even using of inactive catalytic mutants of the enzyme (unpublished). The modulatory effect on PS1 levels was not sustained when AChE-I promotes feedback AChE upregulation (Silveyra et al. 2012b ). All together these results suggest that excess of inactive or inactivated brain AChE can exert a variety of unpredictable effects and may induce vulnerability in the pathological brain. In conclusion, a better understanding of the alternative functions of AChE and estimation of its protein levels could be relevant for deciphering their implication in the progression of Alzheimer's pathology and the development of new therapy.
